PlasmaTech Biopharmaceuticals, Inc. announces closing of Public
Offering
29/12/2014 18:15
A biopharmaceutical company advancing patient care in critical areas, PlasmaTech Biopharmaceuticals, Inc. today said that the closing of an underwritten public offering of 3,500,000 shares of common stock, and warrants to purchase up to an aggregate 3,500,000 shares of common stock, at an offering price of USD 4.00 per share and USD .01 per warrant, reported media. The gross proceeds to the Company from this offering were USD 14,035,000, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares and warrants in the offering were sold by the Company. The shares and warrants began trading on The NASDAQ Capital Market on December 19, 2014 under the symbols "PTBI" and "PTBIW," respectively. Commenting on the development, Scott Schorer, CEO of PlasmaTech Biopharmaceuticals, Inc. stated, "We are pleased to be moving forward with the next stage of PlasmaTech's development, and look forward to delivering on the promise of our exciting technology platforms." H.C. Wainwright & Co. and Aegis Capital Corp. are acting as joint book-running managers for this offering.
29/12/2014 18:15
A biopharmaceutical company advancing patient care in critical areas, PlasmaTech Biopharmaceuticals, Inc. today said that the closing of an underwritten public offering of 3,500,000 shares of common stock, and warrants to purchase up to an aggregate 3,500,000 shares of common stock, at an offering price of USD 4.00 per share and USD .01 per warrant, reported media. The gross proceeds to the Company from this offering were USD 14,035,000, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares and warrants in the offering were sold by the Company. The shares and warrants began trading on The NASDAQ Capital Market on December 19, 2014 under the symbols "PTBI" and "PTBIW," respectively. Commenting on the development, Scott Schorer, CEO of PlasmaTech Biopharmaceuticals, Inc. stated, "We are pleased to be moving forward with the next stage of PlasmaTech's development, and look forward to delivering on the promise of our exciting technology platforms." H.C. Wainwright & Co. and Aegis Capital Corp. are acting as joint book-running managers for this offering.
